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ABSTRACT 
Epilepsy is a common chronic neurological disorder and it imposes a 
big burden on health care systems. It is treated mainly with drugs but 
surgery may be used for severe cases. Sodium valproate is widely 
used as a major drug in the treatment of epilepsy, but the most serious 
adverse effect of chronic use is hepatotoxicity.  
The objective of this study was to investigate the effects of Gum 
Arabic on sodium valproate-induced hepatotoxicity in the rat, by 
following liver function during treatment. 
Twenty eight healthy rats weighing 80 – 160 g were divided into four 
groups and received treatment for 45 days. Group (A) was given 
sodium valproate orally at dose of 2.2 mg/kg  body weight (B.wt) 
/rat/day. Group (B) was given sodium valproate 2.2 mg/kg body 
weight /rat/day and Gum Arabic 0.5 g/kg body weight (B.wt)/rat/day 
in drinking water simultaneously. Group (C) was given water and 
served as control for group (A). Group (D) received Gum Arabic at 
0.5 mg/kg body weight (B.wt) /rat/day in drinking water. Alanine 
amino transferase (ALT), aspartate amino transferase (AST), alkaline 
phosphatase, (ALP), total plasma proteins, albumin and total bilirubin 
were estimated with Roche Diagnostic/ Hitachi (902) system. 
The results showed that serum ALT and AST activities in group (A) 
receiving valproate increased significantly (P< 0.01) after 15 days, 30 
days (P< 0.001) and 45 days (P< 0.0001).  
Treatment with Gum Arabic in combination with valproate (group B) 
resulted in a significant increases in the level of ALT and AST after 
30 and 45 days compared to the control D (P<0.01). Although levels 
of ALT and AST increased, the values were significantly decreased 
compared to the corresponding estimates of group (A). 
A highly significant increase in the level of ALP was found in group 
(A) after 15, 30 and 45 days compared to the control. Although 
treatment with valproate in combination with Gum Arabic resulted in 
a significant rise in ALP level throughout the period of treatment; the 
rise was significantly lower than that recorded for group (A) at the 
respective times. Serum total protein concentration showed no 
significant difference between groups A, B, C, and D throughout 
treatment. However, a significant decrease in the level of albumin in 
group A was found after 30 and 45 days (P=0.01 and P= 0.001 
respectively). Combination therapy restored the decrease that occurred 
viii 
 
at 30 and 45 days in valproate treatment to normal. There was a highly 
significant increase in the level of total bilirubin concentration in 
group (A) after 30 days (P= 0.001) and 45 days (P=0.0001)). There 
was significant decrease in the level of total bilirubin concentration in 
group B compared to group A. 
The present study showed that Gum Arabic has protective effect on 
sodium valproate- induced hepatotoxicity in rats. This is manifested 
by the effects on valporoate treatment in reducing the increasing levels 
of transaminases and alkaline phosphatase, restoration of albumin as 
well as of bilirubin to almost normal levels. 
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 ﺍﻟﻤﻠﺨﺹ 
اﻟﺼﺮع ﻣﻦ اﻹﺿﻄﺮاﺑﺎت اﻟﻌﺼﺒﻴﺔ اﻟﻤﺰﻣﻨﺔ اﻷآﺜﺮ ﺷﻴﻮﻋًﺎ، وهﻮ ﻳﻔﺮض ﻋﺒﺌﺎ آﺒﻴﺮا ﻋﻠﻲ 
أﺳﺎﺳﺎ وﻟﻜﻦ اﻟﺠﺮاﺣﺔ ﻗﺪ ﺗﺴﺘﻌﻤﻞ ﻟﻠﺤﺎﻻت  أﻧﻈﻤﺔ اﻟﺮﻋﺎﻳﺔ اﻟﺼﺤﻴﺔ ، وهﻮ ﻳﻌﺎﻟﺞ ﺑﺎﻟﻌﻘﺎﻗﻴﺮ
وﺗﺴﺘﺨﺪم ﻓﺎﻟﺒﺮوات اﻟﺼﻮدﻳﻮم ﻋﻘﺎرا رﺋﻴﺴﻴﺎ وﺑﺸﻜﻞ واﺳﻊ ﻓﻲ ﻣﻌﺎﻟﺠﺔ اﻟﺼﺮع ، ﻟﻜﻦ  اﻟﺤﺎدة،
  .اﻟﺘﺄﺛﻴﺮ اﻟﻤﻀﺎد واﻷآﺜﺮ ﺧﻄﻮرة ﻟﻼﺳﺘﻌﻤﺎل اﻟﻤﺰﻣﻦ هﻮ ﺗﺴﻤﻢ اﻟﻜﺒﺪ
ﺴﺒﺒﺔ ان اﻟﻬﺪف ﻣﻦ هﺬﻩ اﻟﺪراﺳﺔ هﻮ ﻣﻌﺮﻓﺔ ﺗﺄﺛﻴﺮ اﻟﺼﻤﻎ اﻟﻌﺮﺑﻲ ﻋﻠﻲ ﻓﺎﻟﺒﺮوات اﻟﺼﻮدﻳﻮم اﻟﻤ
  .ﻟﺘﺴﺴﻢ اﻟﻜﺒﺪ ﻓﻲ اﻟﻔﺌﺮان ، و ذﻟﻚ ﻣﻦ ﺧﻼل ﻣﺘﺎﺑﻌﺔ وﻇﺎﺋﻒ اﻟﻜﺒﺪ أﺛﻨﺎء اﻟﻤﻌﺎﻟﺠﺔ
 061 - 08اﺑﻴﻀﺎ ﺳﻠﻴﻤﺎ ﻟﻠﺪراﺳﺔ ، ﺗﺰن  ﻓﻲ هﺬﻩ اﻟﺘﺠﺮﺑﺔ ﺗﻢ إﺧﻀﺎع ﺛﻤﺎﻧﻴﺔ وﻋﺸﺮﻳﻦ ﻓﺄرا
أﻋﻄﻴﺖ ( أ)ﻳﻮم ﻣﺠﻤﻮﻋﺔ  54ﺟﺮاﻣﺎ وﻗﺪ ﻗﺴﻤﺖ إﻟﻲ أرﺑﻊ ﻣﺠﻤﻮﻋﺎت وأﻋﻄﻴﺖ ﻣﻌﺎﻟﺠﺔ ﻟﻤﺪة 
ﻓﻘﺪ أﻋﻄﻴﺖ ﻓﺎﻟﺒﺮوات ( ب)أﻣﺎ اﻟﻤﺠﻤﻮﻋﺔ .ﻳﻮم/ آﺠﻢ/ ﺠﻢﻣﻠ 2.2ﻓﺎﻟﺒﺮوات اﻟﺼﻮدﻳﻮم 
 /ﺟﻢ 5.ﻳﻮم وﻓﻲ ﻧﻔﺲ اﻟﻮﻗﺖ أﻋﻄﻴﺖ ﺟﺮﻋﺔ ﻣﻦ اﻟﺼﻤﻎ اﻟﻌﺮﺑﻲ / آﺠﻢ/ ﻣﻠﺠﻢ 2.2اﻟﺼﻮدﻳﻮم 
ﻓﺄﻋﻄﻴﺖ ﻣﺎء واﺳﺘﺨﺪﻣﺖ آﻤﺠﻤﻮﻋﺔ ( ج)وأﻣﺎ اﻟﻤﺠﻤﻮﻋﺔ . ﻳﻮم ﻓﻲ اﻟﻤﺎء اﻟﺼﺎﻟﺢ ﻟﻠﺸﺮب /آﺠﻢ
  . ﻳﻮم ﻓﻲ ﻣﺎء اﻟﺸﺮب /آﺠﻢ /ﺟﻢ 5.ﺟﺮﻋﺔ ﺻﻤﻎ ﻋﺮﺑﻲ ( د)آﻤﺎ أﻋﻄﻴﺖ اﻟﻤﺠﻤﻮﻋﺔ .ﺗﺤﻜﻢ 
ﻟﻘﺪ ﺗﻢ ﺗﺤﺪﻳﺪ إﻧﺰﻳﻢ اﻻﻻﻧﻴﻦ أﻣﻴﻨﻮ ﺗﺮاﻧﺴﻔﻴﺮﻳﺰ، أﺳﺒﺎرﺗﻴﺖ أﻣﻴﻨﻮ ﺗﺮاﻧﺴﻔﺮﻳﺰ، واﻟﻔﻮﺳﻔﺘﻴﺰ 
/ اﻟﻘﻠﻮي، اﻟﺒﺮوﺗﻴﻦ اﻟﻜﻠﻲ، اﻻﻟﺒﻮﻣﻴﻦ، واﻟﺒﻠﻴﺮوﺑﻴﻦ اﻟﻜﻠﻲ ﺑﺎﺳﺘﺨﺪام ﻧﻈﺎم روش اﻟﺘﺸﺨﻴﺼﻰ
  (.209)هﻴﺘﺎﺗﺸﻲ 
ﻮ ﺗﺮاﻧﺴﻔﺮﻳﺰواﻻﺳﺒﺎرﺗﻴﺖ اﻣﻴﻨﻮ أوﺿﺤﺖ اﻟﻨﺘﺎﺋﺞ زﻳﺎدة ﻣﻌﻨﻮﻳﺔ ﻓﻲ ﻧﺸﺎط إﻧﺰﻳﻤﺎت اﻻﻻﻧﻴﻦ أﻣﻴﻨ
  .ﻳﻮﻣﺎ  54، وﺑﻌﺪ  ﻳﻮﻣﺎ  03،  ﻳﻮﻣﺎ 51ﺑﻌﺪ ( أ)ﻓﻲ اﻟﻤﺠﻤﻮﻋﺔ  ﺗﺮاﻧﺴﻔﺮﻳﺰ ﻓﻲ اﻟﺴﻴﺮم 
اﻟﻲ زﻳﺎدة ﻣﻌﻨﻮﻳﺔ ﻓﻲ ( ﻣﺠﻤﻮﻋﺔ ب)أدت اﻟﻤﻌﺎﻟﺠﺔ ﺑﻔﺎﻟﺒﺮوات اﻟﺼﻮدﻳﻮم ﻣﻊ اﻟﺼﻤﻎ اﻟﻌﺮﺑﻲ 
، (د)ﻜﻢ ﻳﻮﻣﺎ ﻣﻘﺎرﻧﺔ ﺑﻤﺠﻤﻮﻋﺔ اﻟﺘﺤ 54ﻳﻮﻣﺎ وﺑﻌﺪ  03ﻣﺴﺘﻮي اﻻﻻﻧﻴﻦ واﻷﺳﺒﺎرﺗﻴﺖ ﺑﻌﺪ 
ﺑﺎﻟﺮﻏﻢ ﻣﻦ أن ﻣﺴﺘﻮﻳﺎت اﻻﻻﻧﻴﻦ واﻷﺳﺒﺎرﺗﻴﺖ زادت، اﻻ أن اﻟﻘﻴﻢ ﻧﻘﺼﺖ ﻣﻌﻨﻮﻳﺎ ُﻣَﻘﺎَرﻧﺔ ﺑﺘﻠﻚ 
   (أ)اﻟﻘﻴﺎﺳﺎت اﻟﻤﻄﺎﺑﻘﻪ ﻓﻲ اﻟﻤﺠﻤﻮﻋِﺔ 
( أ)زﻳﺎدة ﻣﻌﻨﻮﻳﺔ  آﺒﻴﺮﻩ ﻓﻲ ﻣﺴﺘﻮي اﻟﻔﻮﺳﻔﺘﻴﺰ اﻟﻘﻠﻮى ﻓﻲ اﻟﺴﻴﺮم ﻓﻲ اﻟﻤﺠﻤﻮﻋﺔ  هﻨﺎك ُوِﺟﺪْت
وﺑﺎﻟﺮﻏﻢ ﻣﻦ أن اﻟﻌﻼج ﺑﻔﺎﻟﺒﺮوات . ﺤﻜﻢﻳﻮﻣﺎ ﻣﻘﺎرﻧﺔ ﺑﻤﺠﻤﻮﻋﺔ اﻟﺘ 54و 03،  51ﺑﻌﺪ 
أدى اﻟﻲ ارﺗﻔﺎع ﻣﻌﻨﻮي ﻓﻲ ﻣﺴﺘﻮي اﻟﻔﻮﺳﻔﺘﻴﺰ ( ﻣﺠﻤﻮﻋﺔ ب)اﻟﺼﻮدﻳﻮم ﻣﻊ اﻟﺼﻤﻎ اﻟﻌﺮﺑﻲ
،اﻻ أن هﺬا اﻹرﺗﻔﺎِع َآﺎَن ﻣﻨﺨﻔﻀﺎ (د)اﻟﻘﻠﻮى ﺧﻼل ﻓﺘﺮة اﻟﻤﻌﺎﻟﺠﺔ ﻣﻘﺎرﻧﺔ ﺑﻤﺠﻤﻮﻋﺔ اﻟﺘﺤﻜﻢ 
ﻟﻴﺲ هﻨﺎك إﺧﺘﻼﻓﺎ ﻣﻌﻨﻮﻳﺎ . ِتﻓﻲ ﻧﻔﺲ اﻷوﻗﺎ( أ)ﻣﻌﻨﻮﻳﺎ ﻋﻦ اﻟﻤﺴﺘﻮﻳﺎت اﻟﺘﻲ ﺳّﺠﻠَﺖ ﻟﻠﻤﺠﻤﻮﻋِﺔ 
وﻟﻜﻦ .ﻋﻦ ﺗﺮآﻴﺰ اﻟﺒﺮوﺗﻴﻦ اﻟﻜﻠﻲ ﻓﻲ اﻟﺴﻴﺮم ﺑﻴﻦ اﻟﻤﺠﻤﻮﻋﺎت أ، ب، ج، د ﺧﻼل ﻓﺘﺮة اﻟﻤﻌﺎﻟﺠﺔ
ﻳﻮﻣﺎ ، وﻟﻘﺪ  54ﻳﻮﻣﺎ و 03ﺑﻌﺪ ( أ)هﻨﺎك ﻧﻘﺼﺎن ﻣﻌﻨﻮي ﻓﻲ ﻣﺴﺘﻮي اﻷﻟﺒﻮﻣﻴﻦ ﻓﻲ اﻟﻤﺠﻤﻮﻋﺔ 
 54ﻳﻮﻣﺎ و 03ﺧﻼل  أﻋﺎَد اﻟﻌﻼُج ﺑﻔﺎﻟﺒﺮوات اﻟﺼﻮدﻳﻮم ﻣﻊ اﻟﺼﻤﻎ اﻟﻌﺮﺑﻲ اﻟﻨﻘﺺ اﻟﺬي َﺣﺪَث
  . ﻳﻮﻣﺎ ﻓﻲ اﻟﻤﺠﻤﻮﻋﺔ اﻟﻤﻌﺎﻟﺠِﺔ ﺑﻔﺎﻟﺒﺮوات اﻟﺼﻮدﻳﻮم ﻟﻠﻤﺴﺘﻮي اﻟﻄﺒﻴﻌﻰ
 x
 
  03ﺑﻌﺪ ( أ)آﺎن هﻨﺎك زﻳﺎدة ﻣﻌﻨﻮﻳﺔ ﻋﺎﻟﻴﺔ ﻓﻲ ﻣﺴﺘﻮي ﺗﺮآﻴﺰ اﻟﺒﻠﻴﺮوﺑﻴﻦ اﻟﻜﻠﻲ ﻓﻲ اﻟﻤﺠﻤﻮﻋﺔ 
( ب)هﻨﺎك ﻧﻘﺼﺎن ﻣﻌﻨﻮي ﻓﻲ ﻣﺴﺘﻮي ﺗﺮآﻴﺰ اﻟﺒﻠﻴﺮوﺑﻴﻦ اﻟﻜﻠﻲ ﻓﻲ اﻟﻤﺠﻤﻮﻋﺔ .ﻳﻮﻣﺎ  54ﻳﻮﻣﺎ و
  (.أ)ﻤﺠﻤﻮﻋﺔ ﻣﻘﺎرﻧﺔ ﺑﺎﻟ
أوﺿﺤﺖ اﻟﺪراﺳﺔ اﻟﺤﺎﻟﻴﺔ أن اﻟﺼﻤﻎ اﻟﻌﺮﺑﻲ ﻟﻪ ﺗﺄﺛﻴﺮ وﻗﺎﺋﻲ ﺿﺪ ﺗﺴﻤﻢ اﻟﻜﺒﺪ ﻓﻰ اﻟﻔﺌﺮان 
ﻳﻈﻬﺮ ذﻟﻚ ﺑﺘﺎﺛﻴﺮﻩ ﻋﻠىﺎﻟﻌﻼج ﺑﺎﻟﻔﺎﻟﺒﺮوات ﻓﻲ ﺗﺨﻔﻴِﺾ . اﻟﻤﻌﺎﻟﺠﺔ ﺑﻔﺎﻟﺒﺮوات اﻟﺼﻮدﻳﻮم 
ﻟﻰ اﻟﻤﺴﺘﻮﻳﺎت اﻟﻤﺘﺰاﻳﺪة ﻟﻠﺘﺮاﻧﺲ اﻣﻴﻨﻴﺰ و اﻟﻔﻮﺳﻔﺘﻴﺰ اﻟﻘﻠﻮى ، و إﻋﺎدة اﻷﻟﺒﻮﻣﻴﻦ واﻟﺒﻠﻴﺮوﺑﻴﻦ إ
  .اﻟﻤﺴﺘﻮﻳﺎت اﻟﻄﺒﻴﻌﻴِﺔ
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INTRODUCTION 
Acacia Gum is exudates of the stems and branches of acacia 
trees (family leguminacae) and it is often referred to commercially as 
Gum Arabic. It is a fermentable polysaccharide resistant to gut 
enzymes and thus can be described as a dietary fiber (Phillips, 1998). 
It is a high molecular weight polysaccharide containing D-
galactopyranose, D-glucuronic acid, L-rahamnopyanose and L-
arabofuranose, beside a protein portion. The exact structure is not yet 
depicted but believed to be a protein core from which polysaccharide 
chains ramify. 
 It is extensively used in the food industry in a wide range of 
products including sweets, soft drinks and beverages, exploiting its 
demulcent, emulsifying and binding properties. It is also used in 
pharmaceutical preparations for the same properties. Recently it has 
been indicated as a supportive therapy in chronic renal failure (Ali     
et al., 2008). In 1999, Gum Arabic was introduced as a supportive 
therapy for chronic renal failure patients in Sudan by a group of 
doctors headed by Professor Salma M. Sulieman (Sulieman, 1999), a 
consultant medical Physician at Khartoum Dialysis and Kidney 
Transplantation Center. 
Gum Arabic is generally recognized as safe with no recognized toxic 
effects (Sheu et al., 1986 and Campbell et al., 1997). It is neither 
teratogenic nor carcinogenic (National Toxicology Program, 1982) or 
allergic (Sander et al., 2006). Gum Arabic has been shown to have 
protective effect against the toxicity of a number of drugs. (Abd-Allah  
et al., 2002; Al-Majed et al., 2002; Gamaleldin et al., 2003 and Al-
Majed et al.,  2003) 
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Epilepsy:  
Epilepsy is a common disorder, characterized by seizures, which take 
various forms and result from episodic neuronal discharges. It affects 
approximately 1% of the population. It is treated mainly with drugs 
but surgery may be used for severe cases. Current antiepileptic drugs 
such as phenytion, carbamazepine, valproate and ethosuximide are 
effective in controlling seizures in about 70–80% of patients, but their 
use is often limited by side effects (Eadie and Vajda, 1999). One of 
the drugs extensively used is sodium valproate (VPA). Such extensive 
use is justified by the drug efficacy against a wide range of seizure 
disorders. It appears to be well tolerated in therapeutic doses; 
however, close monitoring of patients treated with the drug for 
hepatotoxic effects is a common practice by physicians and 
neurologists. It has been shown that valproate induces hepatotoxicity 
(Gerstner et al., 2008).  
Independent risk factors for valproate hepatotoxicity are poly therapy 
with other antiepileptic drugs and over dosage (Kondo et al., 1992, 
Lippincott and Wikins, 2003). Since there are no laboratory tests, 
which detected early toxicity, it is prudent to avoid valproate in these 
risk patients.  
It has been reported that Gum Arabic has hepatoprotective effects 
against certain drugs (Gamal-eldin et al., 2003). It is worth-while to 
probe this aspect in connection with valproate by investigating the 
effect of Gum Arabic supplementation in patients receiving valproate 
as a sole medication or in combination therapy. From a pure ethical 
stand one would rather do this protocol in an animal model that gives 
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results, which can be extrapolated to the human situation. The most 
eligible animal candidate in this situation is the rat.  
Objectives:  
General objective in this study is to investigate the effects of 
Gum Arabic oral treatment on sodium valproate hepatotoxicity in the 
rat, by following liver function during treatment with the drug.  
Assessment of liver function will be followed by: 
1. Measurements of the activity of liver enzymes such as Alanine 
amino Transferase (ALT), Aspartate Amino Transferase (AST) 
and Alkaline Phosphatase. 
2. Total proteins and Albumin. 
3. Estimation of Bilirubin. 
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CHAPTER ONE 
LITERATURE REVIEW 
 
1.1 Gum Arabic  
1.1.1 Definition 
Gum Arabic (GA) is a dietary fiber derived from the dried exudates 
obtained from the stems and branches of natural strains of Acacia 
Senegal (L.) or Acacia seyal (family leguminosae). Sudan is the 
world’s largest producer of Gum Arabic, principally in the traditional 
rainfed areas of western Sudan. The best grade of Gum Arabic comes 
from cultivated trees (garden gum or hashab), known as Kordofan 
Gum (Fig. 1).  
Gum Arabic is generally recognized safe as a direct food additive, as 
it has shown negative genotoxicity effects (Sheu et al., 1986). It has 
never proved to be a reproductive or developmental toxin (WHO, 
2000) and is not carcinogenic (Campbell et al., 1997) when given 
intraperitoneally or orally.  
Acacia has long been used in traditional medicine. Arabic physicians 
treated a wide variety of ailments with Gum. To day, it is used widely 
in pharmaceutical and food industry as emulsifier, adhesive, and 
stabilizer (Leung 1980; Smolinske and Susan 1992). 
1.1.2 Chemical constituents and properties 
Acacia Gum is a brittle, odorless, pale colour, tasteless, and is soluble 
in water forming transpartant viscous solution, but insoluble in ethanol 
and other organic solvents (FAO, 1995).  
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Fig . (1): Kordofan Gum Arabic (left raw Gum and right spray-dried 
powder) 
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Chemically, GA is complex polysaccharide consisting mainly of 
calcium salts of ploy Arabic acid, but also contains magnesium and 
potassium ions (Onishi et al., 2008; Nasir et al., 2008). 
Gum Arabic described by Phillips and Williams (1993) as a large 
molecule with high molecular weight ranging from 300 to 800 Kilo 
Daltons. It consists of carbohydrate moieties made of L-rhaminose 
(12.2-14%), L-Arabnose (26-28%), D-galactose (40-44%) and D-
glucuronic acid (15.5-16%). These carbohydrate moieties are 
covalently attached to a protein backbone (2%) which contains 
hydroxy proline (Anderson et al., 1985).         
The main chemical and physical features of the Acacia senegal Gum 
and its molecular fractions isolated by chromatographies were 
determined using a wide variety of methods. Three main molecular 
fractions were isolated after hydrophobic interaction chromatography 
(HIC) and biochemical analyses confirmed the presence of an 
arabinogalactan-peptide (FI) an arabinogalactan-protein (FII), and a 
glycoprotein (FIII). Estimation of the polypeptide backbone length in 
the three fractions gave 43, 2253, and 4443 amino acid residues, 
respectively, hydroxyl proline (Hyp) and serine being the most 
prominent residues within FI and FII, Hyp and Asx (asparagine + 
aspartic acid) within FIII (Renard et al., 2006). 
1.1.3 Biological aspects 
1.1.3.1 Absorption and metabolism 
Gum Arabic is primarily indigestible to both human and animals as it 
is not degraded in the intestine, but fermented in the colon under the 
influence of microorganisms (Phillips, 1998). The literature indicates 
7 
 
that Gum Arabic can be fermented by intestinal bacteria to short chain 
fatty acid, particularly propionate (Kishimoto et al., 2006).  
1.1.3.2 Toxicological studies 
 Gum Arabic has no teratogenic or carcinogenic properties (National 
Toxicology Program, 1982). In rats, GA has no histo-pathological or 
hematological toxicity when administered for 13 weeks at doses as 
high as 5 g/kg/day. It has been shown that GA has no effect on 
concentration of some free-scavengers (reduced glutathione, ascorbic 
acid, lipid perodxidation and the free radical scavenger enzyme 
superoxide dismutase) on the kidney and liver in healthy rats (Abd-
Allah et al., 2002; Al- Majed et al., 2003).  
1.1.4 Protective effects of Gum Arabic 
Gum Arabic has been shown to have a protective effect     against the 
toxicity of a number of drugs. GA has recently been claimed to be 
effective in preventing gentamicin-induced acute renal failure in rats. 
It has been suggested that the renoprotective effect of GA is possibly 
through inhibition of the production of free-radicals that cause 
perodxidation (Ali 2004). It has also been reported that   GA has 
protective effect against cardiotoxicity induced by doxorubicin. This 
was evidenced by significant reduction in serum creatine kinase and 
cardiac lipid peroxides (Abd-Allah et al., 2002). In addition to the 
above GA is effective in protecting mice against acetaminophen-
induced hepatotoxicity (Gamaleldin et al., 2003). Mice were given 
Arabic Gum orally at a concentration of 100 g per L, 5 days before a 
hepatotoxic dose of acetaminophen (500 mg per kg) that is 
administered intraperitoneally. Arabic Gum administration 
dramatically reduced acetaminophen-induced hepatotoxicity as 
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evidenced by reduced serum alanine (ALT) and aspartate amino-
transferase (AST) activities. Nonetheless, Acetaminophen-induced 
hepatic lipid peroxidation was also significantly reduced by GA 
pretreatment (Gamaleldin et al., 2003).                                    
1.1.5 Uses of Gum Arabic 
1.1.5.1 Food industry  
The major uses of Gum Arabic are in the food industry where it is 
used as food additive to improve desirable properties through its 
influence on viscosity, body and texture of food .In addition, it is non 
toxic, odorless, colorless, tasteless, and completely water soluble and 
dose not effect the flavor, odour, or color of the food to which its 
added (Fig. 2). 
* Confectionery: GA is extensively used in the confectionery 
industry because its has ability to prevent crystallization of 
sugar also because of its thickening effect. It is used as a 
glaze in candy products (Leung, 1980). 
* Dairy Products: It is used as emulsifier and stabilizer for 
frozen dietary products such as ice cream, because of its 
water absorbing properties (Leung, 1980). 
* Bakery Products: Gum Arabic is widely used in the baking 
industry for its viscosity and adhesive property. It is used 
in glazes and toppings. It also adds smoothness when used 
as an emulsion stabilizer (Leung, 1980). 
* Beverages: It also acts as a source of soluble fiber in low 
caloric and dietetic beverages (Phillips, 1998). Hence in 
such a manner it replaces calorific foods.  
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Fig  (2): Uses of Gum Arabic in food industry 
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1.1.5.2 Medicinal uses 
1.1.5.2.1 Renal 
Gum Arabic was introduced as a supportive therapy for chronic renal 
failure patients in Sudan by a group of doctors headed by Professor 
Salma M. Suliman at Khartoum Dialysis and Kidney Transplantation 
Center (Sulieman, 1999). Results from other workers indicated 
significant increases in creatinine clearance and altered electrolyte 
excretion (Ali 2004; Ali et al., 2008; Nasir et al., 2008). 
1.1.5.2.2 Cholesterol management 
GA has been shown to lower the cholesterol levels in the blood (Ross 
et al., 1983; Mee and Gee, 1997). Specifically that fraction transported 
by low density lipoproteins (LDL) (Marlett, 2001). The mechanism by 
which these fiber sources lower blood cholesterol levels has been the 
focus of many investigations, and characteristics such as solubility in 
water, viscosity, fermentability, and the kinds and amounts of protein. 
The one characteristic common to all cholesterol-lowering fibers is 
viscosity (Marlett, 1998). This viscosity interferes with bile acid 
absorption from the ileum (Marlett et al., 1994). In response, LDL 
cholesterol is removed from the blood and converted into bile acids by 
the liver to replace the bile acids lost in the stool. Some evidence also 
indicates that ingestion of some viscous fibers slowing cholesterol 
synthesis (Moundras et al., 1994). 
1.1.5.2.3 Blood sugar lowering effects  
GA has been shown to lower the glucose levels in the blood (Freed 
and Joffe, 2000).  Researchers found that Gum Arabic lowered 
postprandial serum glucose levels at least by three mechanisms. First, 
the dietary fiber increases the viscosity of small intestine juice and 
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hinders diffusion of glucose. Second, GA binds glucose and decreases 
the concentration of available glucose in the small intestine. Third, it 
retards α-amylase action through capsuling starch and the enzyme  
and might directly inhibit the enzyme. All of these decreased the 
absorption rate of glucose and the concentration of postprandial serum 
glucose (Shiyi et al., 2001).  
The use of high-fiber diets in diabetic patients has long been indicated 
and well documented (Chandalia et al., 2000; Tabatabai and Li 2000 
McIntosh and Miller 2001). 
1.1.5.2.4 GA and electrolyte and water absorption 
Gum Arabic is reported to enhance the movement of water and 
electrolytes such as water and sodium from the intestinal system to the 
blood (Turvil et al., 2000). Another benefit of the Gum Arabic is that 
its use does not change the viscosity of the final solution (Turvil et al., 
2000). 
1.1.5.3. Pharmaceutical Uses 
Gum Arabic is listed in the U.S pharmacopeia as effective suspending 
aid and has been employed suspend insoluble drugs and to prevent the 
precipitation of the heavy metals from solution through formation of 
colloidal suspensions.   
GA was one of best emulsifying agent and suspending agents for 
calamine suspensions, kaolin suspensions, liquid petroleum emulsions 
and cod liver oil emulsions. 
Gum Arabic’s demulcent or soothing characteristics have led to its use 
in many pharmaceutical types of syrup, and used as an adhesive, 
binder for pharmaceutical tablets (Smolinske and Susan, 1992). 
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1.1.5.3.1. Improves gold Nanoparticles for cancer imaging  
It has been shown that Gum Arabic could effectively stabilize gold 
nanoparticles in the body. The investigators noted that over 98 percent 
of the gold salt was converted to Gum Arabic-labeled gold 
nanoparticles. The resulting nanoparticles were stable in biological 
fluids for at least seven days (Kattumuri et al., 2007).  
1.1.5.3.2. Cosmetics 
Non toxic nature and free from dermatological and allergic reactions 
of Gum Arabic has made its use in cosmetics. In lotions and protective 
creams, Gum Arabic adds as smoothing feel to the skin and forms a 
protective coating. It also acts an adhesive in preparation of facial 
masks. It acts as a binder in face powder compacts, while in protective 
creams it is effectively used as stabilizer (Smolinske and Susan, 
1992). 
1.1.5.4. Other uses 
• Paints 
Gum Arabic liquid should be mixed into paint before use, especially 
water-based paint. Gum Arabic makes the colors brighter and lighter.                   
• Inks  
GA has excellent protective colloidal properties. It is added to fabric 
and laundry marking inks to bring these to a desired viscosity for 
smooth printing on cloth. Water colour inks, quick dry inks, 
typographic inks, glass finish inks, all contain Gum Arabic. 
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• Adhesives 
 GA has been widely used in adhesives. Its glues are light in colour, 
odourless, very stable. The adhesive strength of the Gum can also be 
improved by addition of the certain metal salts, such as calcium nitrate 
and aluminum sulphate.GA also finds use in the wall paper, pastes, 
where it’s used in form of a mixture.  
1.2 Sodium Valproate 
Sodium valproate  is a broad-spectrum antiepileptic drug (AED)  that 
has been used for more than 30 years and is effective in the treatment 
of many different types of partial and generalized epileptic seizure 
(Johannessen and Johannessen, 2003). However, serious 
complications may occur in some patients receiving valproate 
chronically. These include fatal hemorrhagic pancreatitis (Moreiras et 
al., 1999), bone marrow suppression (Kishi et al., 1994), VPA-
induced hepatotoxicity (VHT) (Gerstner et al., 2008), and VPA-
induced hyperammonaemic encephalopathy (VH E) (Young et al., 
2007; Rousseau et al., 2009). 
1.2.1 Chemistry 
Valproic acid is one of a series of fatty carboxylic acids (2-
propylpentanoic or di-n-propylacetic acid). Its structure is very similar 
to that of short chain fatty acids (Fig. 3).  
The acid has antiseizure activity, which appears to be greatest for 
carbon chain lengths of five to eight atoms. Branching and 
unsaturation do not significantly alter the drug's activity but may 
increase its lipophility, by increasing its duration of action (Levy,      
2002).  
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   Fig. (3): Chemical structure of Sodium valproate. 
source: (Levy, R.H.(2002): Antiepileptic drugs, 5th Edition, Lippincott 
Williams and Wilkins) 
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1.2.2 Mechanism of action 
VPA increases the levels of gamma-aminobutyric acid and prolongs 
the recovery of inactivated sodium channels. These properties may be 
responsible for its action as a CNS depressant.  
* VPA interacts with voltage-sensitive sodium channels. Their 
blocking action shows the property of use-dependence, in other 
words, they block the excitation of cells that are firing 
repetitively and the higher frequency of the firing, the greater 
the block produced.  
* VPA potentiates γ-aminobutyric acid (GABA) functions in 
some specific brain regions that are thought to be involved in 
the control of seizure generation and propagation by increasing 
both GABA synthesis and release (Bolans and Medina,1997). It 
reduces the release of epileptogenic γ-hydroxybutyric acid and 
attenuates the neuronal excitation induced by N-methyl-D-
aspartate (NMDA)-type glutamate receptors (Loscher, 2002).  
1.2.3 Pharmacokinetic 
1.2.3.1 Absorption 
Non-enteric-coated preparations of VPA are rapidly and nearly 
completely absorbed from the gastrointestinal tract, with peak plasma 
concentrations occurring 1 – 4 hours after ingestion (Graudins and 
Aaron, 1996).  
1.2.3.2 Distribution and protein binding 
The volume of distribution (Vd) is 0.1-0.5 L/kg, with most of the 
quantity of VPA confined to the extracellular space. After an 
overdose, protein-binding sites are saturated, increasing the free 
fraction of VPA and Vd. At such therapeutic concentrations VPA is 
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80–90% bound to plasma proteins, but the percentage decreases at 
higher VPA levels (Levy, 2002). 
1.2.3.3 Metabolism 
VPA is extensively metabolized by the liver via glucuronic acid 
conjugation, mitochondrial β– and cytosolic (endoplasmic reticulum) 
ω-oxidation to produce multiple metabolites, some of which may be 
biologically active (Lheureux, et al., 2005) (Fig. 4). Mitochondrial β-
oxidation of VPA involves its transport within to the mitochondrial 
matrix, using the same pathway, as do long-chain fatty acid the 
'carnitine shuttle' (Fig. 5). 
Less than 3% of VPA is excreted unchanged in the urine (Brubacher 
et al., 1999). Much of which is in the form of valproyl-carnitine 
(Hiraoka et al., 1997).  
Elimination of VPA follows first-order kinetics, with a half-life 
ranging from 5 to 20 hours (mean 11 hours). However, following 
overdose the half-life may be prolonged to as long as 30 hours 
(Mcnamara, 1996).  
1.2.3.4 Therapeutic levels and dosage 
 Dosage of 400 – 600 mg/kg/d may be adequate in some patients but 
other may require over 600 mg/kg/d. Therapeutic serum 
concentrations range from 50 – 100 µg/ml (Levy, 2002).  
1.2.3.5 Drug interactions 
VPA increases serum levels of carbamazepine, Phenobarbital, and 
primidone mainly by inhibiting various cytochrome P450 (CYP450) 
isoenzymes involved in their metabolism. Cimetidine and ranitidine 
increase VPA levels by inhibiting hepatic mixed-function oxidase 
(thereby decreasing VPA metabolism). Drugs that slow the GI  
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Fig. (4): Liver metabolism of valproic acid . 
Source: (Lheureux, et al., (2005): Science review: Carnitine in the 
treatment of valproic acid-induced toxicity – what is the 
evidence? Bio Med Central Ltd. 9: 431-440). 
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Fig . (5): The carnitine shuttle  
Source: (Lheureux, et al., (2005): Science review: Carnitine in the 
treatment of valproic acid-induced toxicity – what is the 
evidence? Bio Med Central Ltd. 9: 431-440). 
 
 
 
 
19 
 
tract may delay absorption of VPA (opiates, antihistamines) during 
co-ingestion (Hachd 2002). 
1.2.4 Toxicity 
The most common dose related adverse effects of sodium valproate 
are nausea, vomiting and other gastrointestinal complaints such as 
abdominal pain and heartburn. A fine tremor is frequently seen at 
higher levels. Other reversible adverse effects seen in small number of 
patients include weight gain, increased appetite, and hair loss 
(Wallace, 2001). Serious complications may occur in some patients 
receiving VAP chronically, including hemorrhagic pancreatitis 
(Moreiras et al., 1999), bone marrow suppression (Kishi, et al., 1994) 
VAP induced hepatotoxicity (VHT) (Fernandez et al., 1995; Gerstner 
et al., 2008), and VAP induced hypermmonaemic encephalopathy 
(VHE) (Young et al., 2007; Rousseau et al., 2009). 
1.2.4.1 Valproate-induced hepatotoxicity (VHT) 
In up to 44% of patients chronic dosing with VPA may be associated 
with elevation in transaminases during the first months of therapy 
(Lippincott, 2003; Goto et al., 2008). The most common clinical 
presentation consists of lethargy, jaundice, nausea, vomiting, 
hemorrhaged, and worsening seizures and anorexia (Bryant and 
Dreifuss, 1996). Histological changes are similar to those observed in 
the Reye's syndrome, with early production of microvesicular steatosis 
accompanied by ultrastructural changes characterized by myeloid 
bodies, lipid vacuoles and mitochondrial abnormalities. 
Risk factors include age under 24 months (especially those with 
organic brain disease), developmental delay, coincident congenital 
metabolic disorders, previous liver dysfunction, or severe epilepsy 
treated with polytherapy or ketogenic diets (Kondo et al., 1992; 
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Gopaul, et al., 2003). The mechanisms of both sub-acute and 
idiosyncratic VHT remain incompletely understood, but it has been 
believed that hypocarnitinaemia, subsequent imbalance between        
β-oxidation and ω-oxidation, and accumulation of 4-en-VPA are 
involved. Additionally, carnitine deficit may result in disruption of 
mitochondrial functions due to depletion in CoA (Coulter, 1991). 
Reduced serum free carnitine as well as reduced levels of 3-keto-
VPA, the main metabolite of β-oxidation of VPA, was first reported in 
1982 by Bohles and coworkers (Bohles et al., 1982) in a 3-year-old 
girl who developed acute liver disease with typical features of Reye’s 
syndrome after treatment with VPA for 6 months. Reduced free 
carnitine and increased serum and urine acylcarnitine levels were also 
demonstrated in patients with VPA-induced Reye-like syndrome 
(Matsuda et al., 1986). In a patient with fatal VHT, Krahenbuhl et al., 
1995 demonstrated a reduction in free and total carnitine in plasma 
and liver. Other mechanisms such as VPA-induced lipid peroxidation 
and glutathione depletion could also contribute to hepatotoxicity 
(Raza  et al., 1997 and Zeitlhofer et al., 2000). Indeed, 4-en-VPA is 
transformed through β-oxidation to reactive intermediates such as     
2-propyl-2, 4-pentadienoic acid (2, 4-dien-VPA) that are capable of 
depleting mitochondrial GSH, as suggested by rat studies (Tong et al., 
2005).  Unsaturated VPA metabolites (4-en-VPA and 2, 4-dien-VPA) 
are potent inducers of microvesicular steatosis in rats. Studies in rats 
also suggested that both VPA and its unsaturated metabolites inhibit 
β-oxidation through different mechanisms, such as sequestration of 
CoA-SH and direct inhibition of specific enzymes in the β-oxidation 
sequence by CoA esters, particularly 4-en-VPA figure (6). 
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Fig. (6): Effects of decreased β-oxidation and increased ω-oxidation of 
fatty acids and VPA on the urea cycle. 
Source: (Lheureux, et al., (2005): Science review: Carnitine in the 
treatment of valproic acid-induced toxicity – what is the 
evidence? Bio Med Central Ltd. 9: 431-440). 
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CHAPTER TWO 
MATERIALS AND METHODS 
 
2.1 Materials 
2.1.1 Animals 
Twenty-eight healthy Wister albino rats of both sexes weighing 80-
160 g were used. They were kept in cages and housed in standard 
environmental conditions of temperature, humidity and light. The rats 
were left for fifteen days adaptation and supplied with standard diet 
and water. 
2.1.2 Gum Arabic 
Gum Arabic was obtained from Gum Arabic Company in Khartoum 
as spray dried powder. 
2.1.3 Sodium Valproate 
Sodium valproate Syrup was obtained from Medico Laboratorys-
Homs- Syria.  Oral solution is an antiepileptic drug for oral 
administration, contains the equivalent of 200 mg/ 5 ml. 
2.1.4 Equipments 
i.  Collection containers. 
ii. Centrifuge. 
iii.  General laboratory equipments. 
iv.  Roche Diagnostic/Hitachi (902) Analyzer 
It is an analyzer, which is used to report results on various body fluid 
samples for a wide range of analyses (Fig. 7). It is fully automated, 
computerized and performs photometric assays. It consists of 
photometric measuring potentiometric system, analytical processing   
units, screen  and  printer.  The analyzer characteristics 
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Fig. (7): Roche Diagnostic/Hitachi (902) Analyzer 
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include: 200 tests per hour and refrigerated storage for 40 reagents 
containers. 
2.1.5 Reagents 
2.1.5.1 Reagents for enzyme analysis 
2.1.5.1.1 Reagents for Alanine aminotransferase (ALT) analysis 
Tris (hydroxymethyl)-amino methane (TRIS) buffer: 125 mmol/l, pH 
7.3; L-alanine: 625 mmol/l; NADH: 0.23mmol/l (yeast); Lactate 
dehydrogenase (LDH) > 1.5 u/ml; Ketoglutarate: 94 mmol/l. 
2.1.5.1.2 Reagents for Aspartate aminotransferase (AST)  
TRIS buffer: 100 mmol/l, PH 7.8; L-aspartate: 300 mmol/l; NADH 
(yeast): 0.23 mmol/l; MDH (porcine heart ≥ 0.53 µ/ml; LDH ≥ 0.75 
u/ml; Ketoglutarate: 75 mmol/l. 
2.1.5.1.3 Reagents for Alkaline phosphatase (ALP) analysis 
2-Amino-2- methyl-1-propanol: 1.12 mol/l, PH 10.44 (30oC); 
magnesium acetate: 2.49 mmol/l; zinc sulfate: 0.50 mmol/l; N- (2-
hydroxyethyl)-ethylnediamine triacetic acid: 2.49 mmol/l; p-Nitro 
phenyl phosphate: 99.5 mmol/l, PH 8.50 (25oC). 
2.1.5.2 Reagents for Total protein estimation 
R1 (Sodium hydroxide: 400 mmol/l; potassium sodium tartrate: 89 
mmol/l). R2 (Sodium hydroxide: 400 mmol/l; potassium tartrate: 89 
mmol/l; potassium iodide: 61 mmol/l; copper sulfate: 24.3 mmol/l. 
2.1.5.3 Reagents for Albumin estimation 
R1 (Citrate buffer: 95 mmol, PH 4.1), R2 (Citrate buffer: 4.1; 
bromocresol green: 0.66 mmol/l. 
2.1.5.4 Reagents for Total bilirubin estimation 
R1 (Sodium acetate buffer: 85 mmol/l; sulfamic acid: 110 mmol/l; 
surfactant; solubilizer, R2 (HCL: 100 mmol/l; diazonium ion: 3 
mmol/l). 
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2.2 Methods 
Activity of enzymes, total protein, albumin, total bilirubin were 
measured by using fully automated apparatus Roche Diagnostics/ 
Hitachi Analyzer (902). 
2.2.1 Experimental design 
At the end of the adaptation period, the rats were divided into 
four groups named, A, B, C, and D. Weighing 80 –160g. 
- Group (A) of eight rats, were treated with sodium valproate at a 
dose of 2.2 mg /kg/ body weight (B.wt) /rat/day for 45 days 
orally. 
- Group (B) of eight rats, were given sodium valproate at a dose 
of 2.2 mg/kg (B.wt)/rat//day and at the same time received Gum 
Arabic at a dose 0.5 g/kg (B.wt)/rat/day in drinking water for 45 
days  
- Group (C) of six rats, were given water for 45 days (served as 
control). 
- Group (D) of six rats, received Gum Arabic at a dose 0.5 mg/kg 
B.wt /rat/day (B.wt) in drinking water 45 days (as a base line). 
2.2.2 Samples 
Blood samples were collected from orbital plexus vein in early 
morning every fifteen days for 45 days. Sera were analyzed for 
activities of transaminase ALT and AST, alkaline phosphatase, total 
protein, albumin and total bilirubin.  
2.2.3 Estimation of enzymes activities 
1. Estimation of Alanine aminotransferase (ALT): 
The Roche Diagnostic/Hitachi (902) system is used for the 
measurement of ALT in serum or plasma. The time required to 
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complete an assay is approximately 10 minutes. Concentration range 
was 4- 600 IU/L with the lower detection limit approximately 4 IU/L.  
Principle: 
ALT catalyzes the transformation of L-Alanine and Oxoglutarate at 
optimal PH (7.3). The pyruvate release in the reaction is transformed 
by Lactate dehydrogenase (LDH) in the presence of NADH coenzyme 
to L-lactate, while the NADH/NAD+ oxido-reductive process show a 
decrease in absorbance at 340 nm. The change in absorbance 
correlates with serum ALT activity (Riemtman and Frankel, 1957). 
L -Alanine + α- Ketoglutarate   Pyruvate + L-Glutamate 
               Pyruvate + NADH + H+   Lactate + NAD+   
2.  Estimation of Aspartate aminotransferase (AST): 
The Roche Diagnostic/Hitachi (902) system is used for the 
measurement of AST in serum or plasma. The time required to 
complete an assay is approximately 5 minutes. Concentration range 
was 4-800 IU/L with the lower detection limit approximately 4 IU/L. 
Principle: 
Two substrates participate in the reaction catalyzed by AST. L-
aspartate and Oxolglutarate with the help of NADH coenzyme. Malate 
dehydrogenase (MDH) contained in the reagent catalyses the 
transformation of Oxalactate released in the first reaction. The oxido-
reductive process of NADH/NAD+ is indicated by a decrease in the 
absorbance at 340 nm. The change in absorbance correlates with AST 
activity (Riemtman and Frankel, 1957). 
α- Ketoglutarate + L –Aspartate  L-Glutamate + oxaloacetate                              
            Oxaloacetate + NADH + H+    L-malate + NAD+    
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3. Estimation of alkaline phosphatase (ALP): 
The Roche Diagnostic/Hitachi (902) system was used for the 
measurement of ALT in serum or plasma. The time required to 
complete an assay is approximately 10 minutes. Concentration range 
was 1- 1200 IU/L with the lower detection limit approximately 0.67 
IU/L. 
Principle: 
In the presence of magnesium and zinc ions, p-nitrophenyl phosphate 
is cleavage by phosphatases into phosphate and p-nitrophenol. The p-
nitrophenol released is proportional to the ALT activity and is 
measured photometrically (Chemie 1972).  
P- nitrophenyl phosphate + H2o   phosphate + p- nitrophenol 
4. Estimation of total protein (T PRO): 
The Roche Diagnostic/Hitachi (902) system was used for the 
measurement of total protein in serum or plasma. The time required to 
complete an assay is approximately 5 minutes. Concentration range 
was 0.2-15 g/dl with the lower detection limit approximately 0.2 g/dl  
Principle: 
Divalent copper reacts in alkaline solution with protein peptide bonds 
to form the characteristic purple-colored biuret complex. Sodium 
potassium tartrate prevents the precipitation of copper hydroxide and 
potassium iodide prevents autoreduction of copper. The color intensity 
is directly proportional to protein concentration, which can be 
determined photometrically (Reinhold, 1953). 
Protein + Cu2+   +     Cu- protein complex 
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5. Estimation of albumin (ALB): 
The Roche Diagnostic/Hitachi (902) system was developed for 
measurement of Albumin in human serum or plasma. The time 
required to complete an assay is approximately 10 minutes. 
Concentration range was 1-7 g/dl with the lower detection limit 
approximately 0.2 g/dl. 
Principle: 
At PH= 4.2, albumin bind with bromocresol green to produce a blue-
green complex. The change in absorbance at 628 nm correlates with 
the concentration of albumin (Spencer and Price, 1977). 
Albumin + BCG      albumin BCG complex 
The analyzer automatically calculates the analyte concentration of 
each sample. Conversion factors: g/dl × 10 = g/l. 
6. Estimation of Total Bilirubin (T.BIL): 
Principle: 
Total bilirubin in the presence of a suitable solubilizing agent, is 
coupled with a diazonium ion in strongly acidic medium (pH= 1-2). 
The intensity of the colored bilirubin produced is Proportional to total 
bilirubin concentration and can be measured photometrically 
(Jandrassik and Grof, 1938).  
2.2.4. Statistical analysis 
Data were entered and analyzed using SPSS (Statistical Package 
for Social Sciences) version 13. Numerical data were expressed as 
means, standard error. Significance of difference between means was 
tested by Student’s Samples t test, or one-way ANOVA, depending on 
the number of compared groups; with a p value of ≤ 0.05 considered 
statistically significant. 
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CHAPTER THREE  
RESULTS 
3.1 Liver Function Tests: 
3.1.1 Enzymes Activities 
Table (1, 2 and 3) show the serum level of ALT, AST and ALP of 
experimental rats after 15, 30 and 45 days treatment. Group (A) of 8 
rats received valproate (2.2 mg/kg/Bwt daily for 45 days. Group (B) 
received Gum Arabic (0.5g/kg) simultaneously with valproate (2.2 
mg/kg/day) for 45 days. Group (C) of 6 rats received water for 45 
days. Group (D) of 6 rats received Gum Arabic (0.5g/kg/day in 
drinking water for 45 days. 
3.1.1.1. Measurement of serum ALT  
Table (1) shows the serum level of ALT in rats receiving valproate 
alone and in combination with Gum Arabic and their respective 
controls. Serum ALT activity was measured at day 0 before starting 
the treatment. There was no significant difference in the four groups 
(A, B, C and D). A significant increase in the level of ALT was found 
in group (A) after 15 day (69.6 ± 2.7 U/L) P<0.01, then ALT showed 
a steady increase after 30 day (261 ± 7.4 U/L) with higher level of 
significant P<0.001 and the level reached a peak at day 45 of 
treatment reaching (302 ± 12.8 U/L) P<0.0001 compared to control. 
Serum ALT level in Group (A) of rats that received sodium valproate 
alone daily for 30 days was almost four times greater than that of the 
control. Upon extension of the treatment to 45 days for the same 
group, serum ALT level was almost five times greater than that of the 
control. 
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  Table (1): Changes in serum ALT activity in rats treated with 
sodium valproate alone and in combination with Gum 
Arabic 
ALT U/L  (Mean ± SE) 
 Groups 
Day 45 Day 30 Day 15 Day 0 
 
302±12.8*** 
n=4 
 
 
261.0±7.4** 
n=8 
 
69.6± 2.7* 
n=8 
 
58.8±0.14 
n=8 
   
         A 
 
128.5±15.7** 
n=6 
 
 
146.8±1.3** 
n=8 
 
61.20±1.6 
n=8 
 
59.3±0.33 
n=8 
 
B 
 
58.4±0.2 
n=6 
 
 
58.5±0.2 
n=6 
 
58.7±0.2 
n=6 
 
57.8±0.2 
n=6 
 
C 
 
59±0.2 
n=6 
 
 
59.9±0.2 
n=6 
 
59.6±0.3 
n=6 
 
58.4±0.4 
n=6 
 
D 
        
       Key: 
* P≤ 0.01       **   P≤ 0.001       ***   P≤ 0.0001     
Group (A) = Received sodium valproate. 
Group (B) = Received sodium valproate +Gum Arabic. 
Group (C) = Received water (control).  
Group (D) = Received Gum Arabic 
n = Number of rats 
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Treatment with Gum Arabic daily for 15 days in combination with 
valproate resulted in no significant difference in the level of ALT 
compared to the control group (D). However after 30 and 45 days of 
treatment, the level of ALT in group (B) was (146.83 ± 1.3 U/L) and 
(128.5±15.7 U/L) respectively. This increase was very significant 
(P<0.001) compared to the control D. However, after 45 days of the 
combination treatment ALT dropped (128.5±15.7 U/L) from the level 
attained after 30 days.  It is worthwhile to note that both the 
magnitude and pattern of change in the level of ALT after 30 and 45 
days of treatment with valproate on its own is significantly different 
from that recorded for the treatment with valproate in combination 
with Gum Arabic. The levels of ALT in group (A) both at 30 and 45 
days were significantly higher than the corresponding levels in group 
(B); almost doubled and tripled in value respectively. Moreover, while 
the level of the enzyme increased steadily during the treatment with 
valproate  reaching 302 ± 12.8 U/L at day 45; the level in the 
combination therapy rose to 146.8 ± 1.3 U/L after 30 days and started 
to fall there after, reaching 128.5 ± 15.7 U/L after 45 days. 
Figure (8) illustrates the findings in Table (1) showing ALT levels in 
the four groups over a period of 45 days. 
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Fig. (8): The level of ALT as affected by treatment with sodium 
valproate alone and in combination with Gum Arabic 
for 45 days  
 
 
 
  
33 
 
3.1.1.2 Measurement of serum AST 
Table (2) shows the serum level of AST in rats receiving valproate 
alone and in combination with Gum Arabic plus the corresponding 
controls. Serum AST activity was measured at day 0 before starting 
the treatment, there was no significant difference in the four groups. A 
significant increase in the level of AST (172.0 ± 0.8 U/L) was found 
in group (A) after 15 days (P< 0.01). More significant increases were 
recorded after 30 days (420.5 ± 6.8 U/L) and 45 days (453.8 ± 19.2 
U/L) of administration of sodium valproate compared to control (P< 
0.001 and P< 0.0001 respectively). Serum AST levels in group (A) 
rats that received sodium valproate daily for 45 days was almost five 
times greater than that of the control. This parallels the changes in 
ALT levels described in the previous section. 
Treatment with Gum Arabic in combination with valproate resulted in 
a significant increase (131.3 ± 1.5 U/L) (P< 0.01) after 15 days 
compared to the control D. However, the level of AST in group (B) 
was (319.9 ± 1.4 U/L) and (235 ± 20.4 U/L) after 30 and 45 days of 
the combination treatment respectively. This increase was very 
significant compared to the control D P< 0.0001 and P< 0.001 
respectively. However at 45 days of treatment AST dropped (235 ± 
20.4 U/L) from the level attained after 30 days.   
It is worthwhile to note that both the magnitude and pattern of change 
in the level of AST after 30 and 45 days of treatment with valproate 
on its own were different from that recorded for the treatment with 
valproate in combination with Gum Arabic. 
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Table (2): Changes in serum AST activity in rats treated with 
sodium valproate alone and in combination with Gum 
Arabic 
AST U/L (Mean ± SE) 
 Groups 
Day 45 Day 30 Day 15 Day 0 
 
453.8±19.2*** 
n=4 
 
 
420.5±6.8** 
n=8 
 
172.0± 0.8* 
n=8 
 
81.6±0.3 
n=8 
 
A 
 
235 ± 20.4** 
n=6 
 
 
319.9 ±1.4*** 
n=8 
 
131.3±1.5* 
n=8 
 
83.4±0.4 
n=8 
 
B 
 
82.6 ±  0.2 
n=6 
 
 
81.4±0.3 
n=6 
 
82.8 ± 0.5 
n=6 
 
83.3±0.4 
n=6 
 
C 
 
84.7 ± 0.6 
n=6 
 
 
86.0 ± 0.8 
n=6 
 
88.4 ± 2.1 
n=6 
 
81.8±0.3 
n=6 
 
D 
 
Key: 
* P≤ 0.01       **   P≤ 0.001       ***   P≤ 0.0001     
Group (A) = Received sodium valproate.  
Group (B) = Received sodium valproate +Gum Arabic.  
Group (C) = Received water (control).   
Group (D) = Received Gum Arabic. 
n = Number of rats. 
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The level of AST increased steadily to reach 453.8 ± 19 U/L after 45 
days of treatment with valproate alone. With the combination 
treatment the highest level was reached at day 30 (319.9 ± 1.4 U/L) 
and dropped there after 45 to (235 ± 20.4 U/L). The levels of AST in 
group (A) were significantly (P< 0.01 and P< 0.001 respectively) 
higher at day 30 and day 45 compared to the corresponding levels of 
group (B) recorded for the same duration. For example AST level was 
found to be 420 ± 6.8 U/L  after 30 days of treatment with valproate 
alone where as for the same duration of treatment using combination 
therapy the level recorded 319.9 ± 1.4 U/L . The reduction in the level 
of AST after 45 days in the combination therapy (235 ± 20.4 U/L) was 
even more pronounced when compared to the level when valproate 
was administered alone.   
Figure (9) illustrates the findings in Table (2) showing AST levels in 
the four groups over a period of 45 days. 
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Fig. (9):  The level of AST as affected by treatment with sodium 
valproate alone and in combination with Gum Arabic 
for 45 days  
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3.1.1.3 Measurement of serum ALP 
Table (3) shows the serum level of ALP in groups of rats receiving 
sodium valproate alone and in combination with Gum Arabic and their 
respective controls. Serum ALP activity was measured at day 0 before 
starting the treatment. There was no significant difference between the 
four groups. The level of ALP in group (A) measured after 15 and 30 
days of treatment with sodium valproate was (326.7 ± 1.2 U/L) and 
(335.8 ± 3.4 U/L) respectively. This is a highly significant increase 
(P< 0.001) compared to the control. An even higher level of 
significance in the increase of serum ALP level was observed after 45 
days of treatment reaching 405 ± 15 U/L (P< 0.0001).  
Group (A) rats that received sodium valproate daily for 15 and 30 
days, serum ALP level was almost three times that of the control. 
Upon extension of the treatment to 45 days for the same group, serum 
ALP level was almost four times of the control. 
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Table (3): Changes in serum ALP activity in rats treated with 
sodium valproate alone and in combination with Gum 
Arabic   
 ALP U/L (Mean ± SE) 
   Groups  
Day 45 Day 30 Day 15 Day 0 
 
405±15.5*** 
n=4 
 
 
335.8 ±3.4** 
n=8 
 
326.7±1.2 ** 
n=8 
 
119.0± 0.3 
n=8 
 
A 
 
306.2±9.3** 
n=6 
 
 
218.1±2.4* 
n=8 
 
202.2±1.4* 
n=8 
 
119.7 ± 0.7  
n=8 
 
B 
 
119.3 ± 0.2 
n=6 
 
 
119.0±0.3 
n=6 
 
118.7±0.4 
n=6 
 
119.3±0.4 
n=6 
 
C 
 
119.8 ± 0.4 
n=6 
 
 
122.4±1.0 
n=6 
 
123.3±1.2 
n=6 
 
118.6±0.3 
n=6 
 
D 
 
Key: 
* P≤ 0.01       **   P≤ 0.001       ***   P≤ 0.0001     
Group (A) = Received sodium valproate.  
Group (B) = Received sodium valproate + Gum Arabic. 
Group (C) = Received water (control).  
Group (D) = Received gum Arabic. 
n = Number of rats. 
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Treatment with valproate in combination with Gum Arabic resulted in 
a significant rise in ALP level after 15 days (202.2 ± 1.4 U/L) and 30 
days (218.1 ± 2.4 U/L) that was almost double the level of serum ALP 
in the control D (P< 0.01). However, a highly significant increase in 
the level of serum ALP level was recorded (306.2 ± 9.3 U/L) after 45 
days of treatment that was three times the level in the control P< 
0.001. Comparing this increase in ALP in group (B) with that of group 
(A) at corresponding duration of treatment, showed that there was a 
66.6% drop in ALP level when combination therapy was applied for 
15 and 30 days reaching a 75% reduction after 45 days of treatment.  
Figure (10) illustrates the findings in Table (3) showing ALP levels in 
the four groups over a period of 45 days. 
3.1.1.4. Comparing Enzymes Activities: 
The pattern of elevation in the level of these three liver enzymes, 
however, differed in magnitude as relevant to treatment duration (Fig. 
11).  
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Fig. (10): The level of ALP as affected by the treatment with 
sodium valproate alone and in combination with Gum 
Arabic for 45 days  
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Fig. (11): Comparison of the patterns of change in the activity of 
ALT, AST and ALP during valproate / valproate + Gum 
Arabic treatment during a period of 45 days 
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3.1.2 Protein 
3.1.2.1 Total protein 
Table (4) shows the serum level of total protein in rats treated with 
valproate alone and in combination with Gum Arabic. Serum total 
protein concentration was measured at 0, 15, 30 and 45 days of 
treatment with valproate. Treatment with valproate for 45 days 
resulted in no significant difference in the level of total protein 
compared to the control.  
Treatment with valporate in combination with Gum Arabic for 15, 30 
and 45 days resulted in no significant difference in the level of total 
protein compared to the control group (D).  
Figure (12) illustrates the findings in Table (4) showing total protein 
concentration in the four groups over a period of 45 day. 
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Table (4): changes in serum total protein value in rats treated   
with sodium valproate and in combination with Gum 
Arabic  
Total protein g/dl (Mean ± SE) 
 Groups 
Day 45 Day 30 Day 15 Day 0 
 
7.1±0.1ns 
n=4 
 
 
7.1±0.1 
n=8 
 
7.2±0.1 
n=8 
 
7.3±0.02 
n=8 
 
A 
 
7.3  ± 0.02 
n=6 
 
 
7.3 ±0.02 
n=8 
 
7.3±0.03 
n=8 
 
7.3±0.01 
n=8 
 
B 
 
7.3 ± 0.01 
n=6 
 
 
7.3±0.02 
n=6 
 
7.3 ± 0.03 
n=6 
 
7.3±0.01 
n=6 
 
C 
 
7.3 ± 0.01 
n=6 
 
 
7.3±0.01 
n=6 
 
7.3±0.02 
n=6 
 
7.3±0.01 
n=6 
 
D 
 
Key: 
ns  =  not significant    
Group (A) = Received sodium valproate.   
Group (B) = Received sodium valproate +gum Arabic. 
Group (C) = Received water (control).  
Group (D) = Received gum Arabic.                        
n = Number of rats 
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Fig. (12): Total protein level as affected by the treatment with 
sodium valproate alone and in combination with Gum 
Arabic for 45 days  
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3.1.2.2 Albumin concentration   
Table (5) shows the serum level of albumin in rats treated with 
valproate alone and in combination with Gum Arabic. After fifteen 
days of treatment with valproate alone no significant difference in the 
level of albumin was observed when compared to control (C). A 
highly significant decrease in the level albumin was found in group 
(A) after 30 (2.8 ± 0.2 g/dl) and 45 (2.4 ± 0.04 g/dl) days of 
administration of sodium valproate compared to control (P< 0.01 and 
P< 0.001 respectively). 
 Treatment with valproate in combination Gum Arabic daily for 15 
days (3.4 ± 0.04 g/dl), 30 days (3.3 ± 0.03g/dl) and 45 days (3.4 ± 
0.1g/dl) resulted in no significant difference in the level of albumin 
compared to the control group (D). The level of albumin after 45 days 
of treatment with valproate in combination Gum Arabic is 
significantly (P< 0.01) increased compared to that recorded for the 
treatment with valproate alone at 45 days.  
Figure (13) illustrates the finding in Table (5) serum albumin level in 
groups over a period of 45 days 
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Table. (5): Changes in serum albumin value in rats treated with 
sodium valproate alone and in combination with Gum 
Arabic  
Albumin g/dl (Mean ± SE) 
 Groups 
Day 45 Day 30 Day 15 Day 0 
 
2.4±0.04** 
n=4 
 
 
2.8± 0.2* 
n=8 
 
3.3±0.1 
n=8 
 
3.4±0.02 
n=8 
 
A 
 
3.4± 0.1 
n=6 
 
 
3.3± 0.03 
n=8 
 
3.4±0.04 
n=8 
 
3.4±0.02 
n=8 
 
B 
 
3.5±0.1 
n=6 
 
 
3.5±0.1 
n=6 
 
3.4±0.1 
n=6 
 
3.5±0.01 
n=6 
 
C 
 
3.5±0.1 
n=6 
 
 
3.4±0.1 
n=6 
 
3.5±0.02 
n=6 
 
3.4±0.01 
n=6 
 
D 
 
Key: 
* P≤ 0.01       **   P≤ 0.001          
Group (A) = Received sodium valproate.  
Group (B) = Received sodium valproate +gum Arabic. 
Group (C) = Received water (control).  
Group (D) = Received gum Arabic.              
n = Number of rats. 
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Fig. (13): Albumin level as affected by sodium valproate alone and 
in combination with Gum Arabic for 45 days 
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3.1.3 Total bilirubin concentration 
Table (6) shows the changes of serum bilirubin concentration in rats 
treated with sodium valproate alone and in combination with Gum 
Arabic. After 15 days of treatment with valproate alone there was 
significant (P< 0.01) increase in the level of total bilirubin when 
compared to control. Total bilirubin showed a steady increase after 30 
days (0.3 ± 0.02 mg/dl) that was significant at P< 0.001 and it reached 
a higher level at day 45 of treatment (0.4 ± 0.001 mg/dl) which was 
significant (P< 0.0001) compared to the control. The rise in serum 
total bilirubin in group (A) rats receiving sodium valproate daily for 
45 days was almost four fold that of the control. 
 Supplementation of Gum Arabic with valproate after 15, 30 and 45 
days resulted in no significant difference in the level of total bilirubin 
compared to the control group (D). Total bilirubin level in group (A) 
was found to be (0.18 ± 0.01 mg/dl, 0.3 ± 0.02 mg/dl and 0.4±0.001 
mg/dl) after 15, 30 and 45 days of treatment with valproate alone 
where as the corresponding levels for group (B) treated with a 
combination therapy recorded (0.13 ± 0.02 mg/dl, 0.14 ± 0.02 mg/dl 
and  0.16 ± 0.003 respectively). Comparing these sets of data there a 
significantly (P< 0.001) remarkable reduction in total bilirubin 
concentrations when Gum Arabic is supplemented. There was a 
33.3% drop in level total bilirubin when combination therapy is 
applied for 15 and 30 days reaching a 50% reduction after 45 days of 
treatment.   
Figure (14) illustrates the findings in Table (6) showing total bilirubin 
concentration in the four groups over a period of 45 days. 
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Table (6): Changes in serum Total bilirubin concentration in rats 
treated with sodium valproate alone and in combination 
with Gum Arabic  
Total bilirubin mg/dl (Mean ± SE) 
 Groups 
Day 45 Day 30 Day 15 Day 0 
 
0.4±0.001*** 
n=4 
 
 
0.3±0.02** 
n=8 
 
0.18±0.01* 
n=8 
 
0.13±0.03 
n=8 
 
A 
 
0.16±0.003 
n=6 
 
 
0.14±0.02 
n=8 
 
0.13±0.02 
n=8 
 
0.13±0.02 
n=8 
 
B 
 
0.14±0.005 
n=6 
 
 
0.13±0.01 
n=6 
 
0.13±0.01 
n=6 
 
0.13±0.01 
n=6 
 
C 
 
0.12 ± 0.007 
n=6 
 
 
0.13±0.02 
n=6 
 
0.14±0.01 
n=6 
 
0.14±0.01 
n=6 
 
D 
  
Key:  
* P≤ 0.01       **   P≤ 0.001       ***   P≤ 0.0001     
Group (A)= Received sodium valproate.  
Group (B)= Received sodium valproate +gum Arabic. 
Group (D)= Received  gum Arabic.  
Group (C) = Received water ( control).              
 n = Number of rats 
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Fig. (14): Total bilirubin level as affected by sodium valproate and 
Gum Arabic treatment for 45 days  
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CHAPTER FOUR 
DISCUSSION 
 
Epilepsy is one of the most common and serious neurological 
disorders. Genetic, congenital, and developmental conditions are 
mostly associated with it among younger patients. Although epilepsy 
occurs in adults, 25% of all cases develop before the age of five 
(Hitiris et al., 2007). Incidence rate increase in resource-poor 
countries; socioeconomically deprived people are at higher risk 
(Sander, 2003). Considering treatment, potential side effects can be 
worse than the disease itself (Hitiris et al., 2007).  
Sodium valproate is widely used as a major drug in the treatment of 
epilepsy, but the most serious adverse effect is hepatotoxicity (Goto et 
al., 2008; Genstner et al., 2008). As clinical usage of VPA increased, 
reports of its hepatotoxicity began to appear. This toxicity ranges from 
mildly increased aminotransferase enzymes in 15 to 30 percent of 
patients to liver failures (Browne,  1980), and death in some patients ( 
Zimmerman and Ihsak, 1982; Konig   et al., 1994). Valproate toxicity 
is thought to be idiosyncratic and metabolic with out an immunologic 
basis (Zafrani and Berthelot, 1982;  Zimmerman and Ihsak, 1982).  
The mechanisms of both sub-acute and idiosyncratic valproate 
hepatotoxicity (VHT) remain incompletely understood, Hepatotoxicity 
is suspected to result from the formation of toxic valproate 
metabolites, (Siemens et al., 1993) or altered antioxidant enzyme 
activities (Graf et al., 1998). It has been believed that 
hypocarnitinaemia, subsequent imbalance between β-oxidation and ω-
oxidation, and accumulation of 4-en-VPA are involved. Additionally, 
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carnitine deficit may result in disruption of mitochondrial functions 
due to depletion in CoA (Coulter, 1991). Valproate hepatotoxicity is 
more common in persons with mitochondrial enzyme deficiencies and 
may be ameliorated by IV administration of carnitine, which valproate 
therapy can deplete. 
Other mechanisms such as VPA-induced lipid peroxidation and 
glutathione depletion could also contribute to hepatotoxicity (Raza      
et al., 1997 and Zeitlhofer et al., 2000). Indeed, 4-en-VPA is 
transformed through β-oxidation to reactive intermediates such as     
2-propyl-2, 4-pentadienoic acid (2, 4-dien-VPA) that are capable of 
depleting mitochondrial GSH, as suggested by rat studies (Tong et al., 
2005).   
The current study was carried out to investigate the effect of Gum 
Arabic on sodium valproate induced-hepatotoxicity in rats.  
4.1 Effects of Gum Arabic on valproate induced hepatotoxicity 
It has been suggested that overdoses of valproate are potentially toxic 
(Geoffrey et al., 2003). Induced alterations in the biochemical 
parameters, usually tested to assess liver function, upon administration 
of sodium valproate were investigated in this study. These included 
enzymes such as alanine transaminase (ALT), aspartate transaminase 
(AST) and alkaline phosphatase (ALP), total protein, albumin and 
bilirubin.  
In this study hepatotoxicity induced by valproate treatment has been 
clearly observed and documented particularly with chronicity of the 
treatment characterized by elevation of ALT, AST, ALP, bilirubin and 
reduction in albumin. This in fact agrees with findings of experiments 
performed in a similar setting and experimental design (Muhamma et 
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al., 2006). This is usually taken care of by physicians treating epileptic 
patients by close monitoring their liver function to make necessary 
dose adjustments (Konig et al., 1998).  
4.1.1 The transaminases (ALT and AST) 
Serum transaminases level is most widely used as a measure of 
hepatic injury. In this study serum transaminases were significantly 
increased in sodium valproate-treated rats. The study demonstrated 
significant hepatocellular damage. This finding is in good agreement 
with previous findings (Genstner et al., 2008). The present study 
showed that administration of Gum Arabic in combination with 
valproate in drinking water daily for 45 days to Wistar rats produced 
significant reduction of valproate-induced hepatotoxicity as evidenced 
by the decrease in serum alanine and aspartate aminotransferase 
activities. This indicates that Gum Arabic has a successful hepato-
protective effect in averting the elevation of both transaminases 
studied induced by valproate. The protective effect being particularly 
pronounced for ALT (a lowering effect ranging from 50% to over 
60%). The protective effect on AST ranged from 25 to 50%. The 
pattern of activity reduction is similar in both enzymes. For both 
enzymes it seems that Gum Arabic exerts its protective effect 
gradually as reflected by a decline after 30 days of continuous 
combination therapy which opposes the steady rise in activity of these 
enzymes measured during single valproate treatment. Whether this 
pattern of change will continue towards normalization of activity as 
the treatment goes on remains to be investigated. This needs to be 
verified by checking the levels of these enzymes after 60, 75, 90 days 
and so on. This finding is in good agreement with previous findings 
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(Gamaleldin et al., 2003) who investigated the effect of Gum Arabic 
on acetaminophen-induced hepatotoxicity in rats. These authors 
reported that ALT, AST were significantly (P<0.001) decreased in 
mice pretreated with Gum Arabic compared to acetaminophen alone. 
If this proves true it provides venues for new epilepsy therapeutic 
formulations. The prospect isn’t far fetched if one takes into 
consideration the use of Gum Arabic both in the food and drug 
industries (Phillips 1998).  
4.1.2 Alkaline phosphatase 
This enzyme is usually found at high concentrations in liver, bone, 
and placenta and in bile ducts. Increased blood ALP can indicate 
damaged or diseased liver tissue but is also seen during normal bone 
growth.  
Serum alkaline phosphatase level in this study like ALT and AST 
increased during the treatment period.  
The pattern of elevation in the level of these three liver enzymes, 
however, differed in magnitude as relevant to treatment duration (Fig. 
11).  
While there was a gradual rise in the level of ALT and AST from a 
low at day 15 to a high at day 45, ALP showed a three fold increase at 
day 15 and remained almost unchanged after 30 days of treatment 
with valproate, then increased to reach a higher level that is almost 
four fold of its level at the start of treatment. The lag phase may 
reflect some biochemical changes pertaining to phase I and phase II 
metabolism of valproate and how this may affect cytchrome P450 
induction. This is in agreement with previous observations by (Tutor-
Crespo, et al., 2002) who studied some indirect biochemical markers 
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in the evaluation of enzymatic induction caused by antiepileptic drugs. 
The pertinent question to the raise about the behavior of the three liver 
enzymes is whether such elevation in activity is due to induction of 
these enzymes or due to liver cell injuries that releases them into the 
circulation. Production of reactive oxygen species has been implicated 
in hepatocyes damage (Thomas et al., 2006). 4-en-VPA is transformed 
through β-oxidation to reactive intermediates such as 2-propyl-2, 4-
pentadienoic acid (2, 4-dien VPA) and believed to be capable of 
depleting mitochondrial GSH in rat studies (Tong et al., 2005). Of 
course GSH is an important cellular antioxidant particularly in 
prevention of biomembranes damage via lipid peroxidation.         
The administration of Gum Arabic in combination with valproate to 
the rats under investigation produced significant reduction in serum 
ALP activities. The overall pattern of reduction in ALP activity when 
combination therapy is used parallels that recorded for ALP activity 
during valproate treatment on its own; a steady rise in the enzyme 
activity throughout the investigation period. However, it differs from 
the pattern of reduction exhibited by the transeaminases; where a 
significant drop was obtained. 
These findings may give an important signal to the protective effect of 
the soluble fiber (GA) against liver damage, particularly if one 
considers the importance of ALT and AST as biomarkers of liver cell 
injuries rather than ALP.  
If one considers the generation of free radicals hypothesis as a cause 
of valproate hepatotoxicity and if one rules out liver enzyme induction 
during valproate administration in the present study, it may be 
suggested that Gum Arabic has antioxidant properties. Other workers 
in fact have suggested this (The superoxide scavenging effect of GA 
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may explain, at least in part, the protective effect of AG against 
cardiotoxicity induced by DOX  (Abd-Allah et al., 2002). 
The protection offered by Gum Arabic does not appear to be caused 
by a decrease in the formation of toxic acetaminophen metabolites, 
which consumes glutathione, because Gum Arabic did not alter 
acetaminophen-induced hepatic glutathione depletion. Aceta-
minophen increased nitric oxide synthesis as measured by serum 
nitrate plus nitrite at 4 and 6 h after administration and Gum Arabic 
pretreatment significantly reduced their formation (Gamaleldin et al., 
2003). 
4.1.3 Total protein and albumin 
There was no significant difference in total protein in all the groups at 
the different durations. However, administration of valproate for 45 
day caused a significant decrease in albumin. This result is in 
agreement with other workers findings (Attilakos et al., 2007).  
The reduction in serum albumin was restored to normal level after 30 
and 45 days of combination treatment. The reduction in albumin is 
surprising in the light of no change in total plasma protein. However, 
it appears inconsistent with oxidative stress resulting in liver cell 
dysfunction that might have affected the production of other proteins 
as well. Formation of toxic metabolites may be involved in the 
protection offered by Gum Arabic does not appear to be caused by a 
decrease in the formation of toxic metabolites, which consumes 
glutathione, because Gum Arabic did not alter acetaminophen-induced 
hepatic glutathione depletion. 
4.1.4 Bilirubin 
 Significantly elevated serum bilirubin was evident in valproate 
treatment as reflected by a four-fold increase in the metabolite serum 
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concentration by the end of the investigation period of 45 days. This is   
indicative of severe hepatotoxicity. This finding is in agreement with 
previous observations (Lippincott Williams and Wikins, 2003), which 
suggested that bilirubiaemia may result from hepatocellular 
dysfunction. The observation that treatment with Gum Arabic resulted 
in significant decreases of serum bilirubin is suggestive of its 
protective effect against valproate-induced hepatotoxicity. This in 
agreement with previous findings. Ray et al., 2006 found that 
administration of the extract of Acacia catechu at doses of (250 
mg/kg) for seven days showed significant hepatoprotective activity 
(P<0.001) in albino rats.  
Valproate treatment resulted in reduction of albumin and an increase 
in bilirubin concentration. Supplementation with Gum Arabic almost 
restored the two biochemical indices to almost their normal values.  
4.2 The effect of valproate prolonged administration  
Duration of valproate administration has significant effects on liver 
function. This is obvious from the results of the serum enzymes ALT, 
AST and bilirubin levels recording 81, 82 and 75%  increase 
respectively after 45 days of valproate treatment as compared to the 
same group tread for 30 days (78 , 80, and 66% respectively), and 15 
days (16, 53 and 44%  respectively). Administration of GA (0.5 g/kg) 
with sodium valproate (group B) produced a significantly protection 
against hepatotoxicity induced by valproate. This was evidenced by 
significant reductions in serum ALT, AST and bilirubin when 
compared to valproate group. 
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Conclusions 
The potential value of Gum Arabic supplements in preventing adverse 
effects of sodium valproate- induced hepatotoxiciy has been clearly 
revealed in this study. Its amelioration of valproate- induced 
hepatotoxiciy is evident liver function tests as it reduced the level of 
serum aminotransferases, alkaline phosphatase, bilirubin and restored 
serum albumin levels.  
 It has been proven that Gum Arabic supplementation produces no 
adverse or harmful effects on human health evidenced by its extensive 
use in both the food and pharmaceutical industries. It emerges from 
this study that it could be a beneficial supplement that can effectively 
counter the valproate-induced hepatotoxicity.  
Recommendations  
 Because of the scarcity of data on the protective effects of Gum 
Arabic and exact mechanisms by which it exerts its action the author 
finds that the following recommendations are worthwhile to consider. 
• Extension of the duration of treatment to further assess the 
protective effect of Gum Arabic in liver transaminases and alkaline 
phosphatase and to examine its potential in restoring their serum 
level to the normal reference value. 
• Further studies are needed to address the reduction in serum 
albumin and to determine the mechanisms involved in VPA-
mediated decrease in serum albumin concentrations. 
• Initiatives by governmental bodies and private sector to make use 
of this important national natural product is highly demanded in 
the direction of designing pharmaceutical formulation of Gum 
Arabic for therapeutic purposes. 
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